Edgestream Partners L.P. Buys Shares of 13,806 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Edgestream Partners L.P. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,806 shares of the biopharmaceutical company’s stock, valued at approximately $3,249,000.

Several other large investors also recently made changes to their positions in the company. New York State Teachers Retirement System acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $1,453,000. Farther Finance Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 95.4% in the third quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 103 shares in the last quarter. QRG Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $221,000. Capital Performance Advisors LLP bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $121,000. Finally, Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth about $29,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $244.52 on Friday. The stock has a market cap of $31.65 billion, a PE ratio of -112.68 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The business has a fifty day simple moving average of $254.70 and a 200-day simple moving average of $261.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research analyst reports. Chardan Capital reissued a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Sanford C. Bernstein dropped their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. HC Wainwright increased their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $310.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $304.26.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,986 shares of company stock valued at $20,397,849. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.